Entellus Medical Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 23rd. The stock was sold at an average price of $19.00, for a total value of $95,000.00. Following the transaction, the director now owns 494,581 shares in the company, valued at $9,397,039. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Entellus Medical Inc. (NASDAQ:ENTL) opened at 18.99 on Tuesday. Entellus Medical Inc. has a 52 week low of $13.72 and a 52 week high of $22.63. The company’s 50-day moving average price is $19.06 and its 200 day moving average price is $18.71. The stock’s market capitalization is $358.23 million.

Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings data on Thursday, November 3rd. The medical technology company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.13. Entellus Medical had a negative net margin of 36.91% and a negative return on equity of 53.20%. The business earned $17.90 million during the quarter, compared to analyst estimates of $17.93 million. During the same quarter in the prior year, the company posted ($0.32) earnings per share. The company’s revenue was up 20.9% on a year-over-year basis. Equities research analysts expect that Entellus Medical Inc. will post ($1.42) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

ILLEGAL ACTIVITY WARNING: “Entellus Medical Inc. (ENTL) Director Brian E. Farley Sells 5,000 Shares of Stock” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of US & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/29/entellus-medical-inc-entl-director-brian-e-farley-sells-5000-shares-of-stock.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Deimos Asset Management LLC acquired a new position in Entellus Medical during the second quarter worth approximately $183,000. Cortina Asset Management LLC boosted its position in Entellus Medical by 39.2% in the second quarter. Cortina Asset Management LLC now owns 421,897 shares of the medical technology company’s stock worth $7,708,000 after buying an additional 118,745 shares in the last quarter. California State Teachers Retirement System boosted its position in Entellus Medical by 36.0% in the second quarter. California State Teachers Retirement System now owns 15,717 shares of the medical technology company’s stock worth $287,000 after buying an additional 4,160 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Entellus Medical by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 17,025 shares of the medical technology company’s stock worth $312,000 after buying an additional 210 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Entellus Medical by 19.6% in the second quarter. Bank of New York Mellon Corp now owns 30,307 shares of the medical technology company’s stock worth $554,000 after buying an additional 4,960 shares in the last quarter. Hedge funds and other institutional investors own 71.55% of the company’s stock.

Several research analysts have commented on ENTL shares. Canaccord Genuity restated a “buy” rating and set a $23.00 price objective on shares of Entellus Medical in a report on Friday, August 5th. BTIG Research reiterated a “buy” rating and issued a $22.00 price target on shares of Entellus Medical in a report on Friday, August 5th. Zacks Investment Research upgraded Entellus Medical from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Monday, August 8th. Finally, Deutsche Bank AG assumed coverage on Entellus Medical in a report on Thursday, October 6th. They issued a “buy” rating and a $26.00 price target on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $22.75.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.

5 Day Chart for NASDAQ:ENTL

Receive News & Stock Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related stocks with our FREE daily email newsletter.